Predictive Oncology (NASDAQ:AGPU) Upgraded by Wall Street Zen to “Hold” Rating

Predictive Oncology (NASDAQ:AGPU) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings raised Predictive Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Predictive Oncology Price Performance

Shares of AGPU stock opened at $7.11 on Friday. Predictive Oncology has a 52-week low of $1.03 and a 52-week high of $32.10. The company has a market cap of $76.93 million, a price-to-earnings ratio of -0.87 and a beta of 3.47. The business’s 50 day simple moving average is $5.83.

Predictive Oncology (NASDAQ:AGPU) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.04 million for the quarter. Predictive Oncology had a negative return on equity of 7,363.67% and a negative net margin of 470,383.31%.

Predictive Oncology Company Profile

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts.